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Methods: Using nationwide administrative registries in Denmark from 2000-2009 we
sought to describe the use of various lower extremity imaging modalities (CTA, MRA,
angiography, and Doppler ultrasound) 1-year prior to lower extremity amputation.
Analysis was limited to patients > 40 years with first amputation for a primary
diagnosis of lower extremity peripheral arterial disease (PAD) or diabetes (DM).
Results: Among the 7,748 patients (58.5% male, mean age 74.1 + 11.6 years) that
underwent an amputation, 5,607 had PAD and 2,141 had DM as the primary cause for
amputation. Use of imaging modalities 1-year prior to amputation was modest; nearly
2/3rd of the amputations were performed without imaging 1 year prior to surgery
(Table). One-year mortality was 33% among patients who were imaged vs 40% among
those who were not. Overall, one-year mortality was 38% (29% for DM and 42% for
PAD).
Rates of Imaging 1-Year Prior to Amputation
Conclusion: The most common imaging modality used 1-year prior to amputation for
PAD or DM was angiography. However, most amputations occur without any imaging
1-year prior to surgery; this represents an opportunity to identify anatomical severity
and modify treatment, especially given the high mortality after amputation.
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Background: Out of 683 AAA operated upon, 120 patients presented with RAAA over
12 years, 42 had REVAR and 78 had OR.
Methods: During 20th century 95% of all AAA were done surgically. However during
21st century 80% of AAA is done endovascularly. Mean Annual number of OR dropped
from 19+/-3.6 to 18+/-7.8,P<0.845, however Mean Annual number of EVARs had
rocketed to 26+/-6.1 P<0.006 . Overall number of AAA repairs has increased by 65%
over twelve years period and number of EVAR has increased by 80% but the absolute
number of RAAA had declined.
Results: Total Emergency mortality rate decreased from 64% to 28.2%. Low Mortality
Rate of 16%for REVAR Vs 32%in OR is due to introduction of an REVAR Programme
which constitutes screening for prevention with early intervention and REVAR for
rupture which has an absolute perioperative mortality reduction of 49% over OR. Table
5 years Survival of Patients with RAAA were 75% REVAR vs. 60% OR (p=0.0205)
Conclusion: Para-Millennium and Contemporary Trends in AAA Management had
shown Increased in Elective EVAR which increased the mortality advantage in favour
of REVAR and it should be Gold standard for RAAA.
TCT-599
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Background: Percutaneous techniques for crossing femoropopliteal chronic total
occlusions (CTOs) offer an alternative to bypass surgery in high-risk patients. The
Wildcat CTO catheter uses a rotating distal tip and deployable wedges to improve
operator device control and create more reliable true lumen passage. We report the
final results of 88 patients enrolled in the Wildcat catheter trial. The FDA recently
granted conditional approval for 50 additional patients which will be incorporated into
the presentation.
Methods: This is a prospective, multicenter, nonrandomized trial. Enrolled patients
with a CTO of the femoropopliteal arteries were unable to be successfully crossed with
initial guidewire techniques. The primary measured efficacy endpoint is guidewire
placement into the true distal lumen after Wildcat passage confirmed by angiography.
Secondary safety/efficacy endpoints were assessed within 30 days. Procedural site
reporting was independently ratified by board-certified angiographic reviewers.
Results: 88 patients were enrolled with an average CTO length of 174 ± 96mm, 89%
of which were de novo lesions. 55% of lesions demonstrated at least moderate
calcification and >85% of vessels were superficial femoral arteries. The device was
used in 84/88 patients. Successful CTO crossing was reported in 89.3% of cases with
95.2% freedom from major adverse events or clinically relevant complications (Table).
Primary Safety
Conclusion: The Wildcat CTO catheter demonstrated an 89.3% crossing rate with little
associated morbidity. Results surpassed study design endpoints.
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The OCELOT Catheter for Long SFA Occlusions–The Six Months Follow Up
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Background: The OCELOT catheter is an atherectomy device with integrated Optical
Coherence Tomography (OCT). By using OCELOT, the operator (while passing the
catheter through-out the occlusion), is oriented in which layer of the vessel he is at the
given moment. It allows to keep the device intraluminal without the subintimal
penetration.
Methods: In August 2010, 10 patients (9 male) with Chronic Total Occlusion (CTO)
of the SFA (length of occlusion between 50-100mm) and claudication distance <200m
underwent 10 endovascular procedures with the use of the OCELOT catheter.
Results: The procedural success was 90%. In one case we were unable to cross the
occlusion because of the severe calcification of the artery. Balloon Angioplasty alone
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